Business
Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization
Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization.
About this update from Sohm, Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Dr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization\r\n \r\n \r\n\r\n\r\nDr. Leonardo Mirandola Joins SOHM, Inc. as an Advisory Board to Advance CAR-T Cell Projects Toward Clinical Trials and Commercialization\r\n\r\n\r\n\r\n\r\n\r\nCHINO HILLS, CA / ACCESS Newswire / May 2, 2025 / SOHM, Inc. (OTC PINK:SHMN), a leading pharmaceutical and biotechnology company specializing in generic drugs and gene-editing tools, proudly announces Dr. Leonardo Mirandola joined the Company as Advisory Board Member. Dr. Mirandola, a biopharma scientist with over a decade of experience in oncology and cell therapy, will spearhead the company's initiatives to advance its CAR-T cell projects toward clinical trials.\r\n Dr. Mirandola brings a wealth of expertise in operational management, R&D, and clinical development, with a proven track record in transforming innovative scientific breakthroughs into viable treatment options. He holds a Ph.D. and a Master's degree from the University of Milano, Italy.\r\n \"Dr. Mirandola's extensive background in cell therapy and his remarkable success in clinical translation make him an invaluable addition to our team,\" said David Aguilar of SOHM Inc. \"His leadership will be instrumental as we push the boundaries of CAR-T cell production and therapy and strive to bring new treatment options to those battling cancer.\"\r\n Before joining SOHM Inc., Dr. Mirandola served as Chief Scientific Officer and Interim Chief Operations Officer at Kiromic Biopharma, where he played a pivotal role in developing and overseeing clinical operations for various groundbreaking therapies. His contributions led to the advancement of an autologous dendritic cell therapeutic vaccine for solid tumors and an allogeneic gamma-delta T-cell therapy, which has received Fast-Track-designation by the FDA and showed positive results in Phase 1 trials for patients with Stage 4 non-small cell lung cancer.\r\n Dr. Mirandola has a remarkable record of securing patents for novel manufacturing techniques and AI-driven target discovery processes, which have significantly advanced the understanding and development of cell therapies. His leadership in establishing cGMP-compliant manufacturing processes will be critical as SOHM Inc. prepares its CAR-...